“Having just entered the landscape three years ago, this achievement is a big step forward for us. We’ve overcome industry-wide hurdles that have previously been holding precision fermentation dairy back, including the production capacity bottleneck and ensuring that unit economics make sense across the supply chain,” said Dr. Eyal Afergan, Imagindairy Co-founder and CEO. “This will enable our customers to put animal-free dairy products on-shelf at cost parity to traditional dairy, without compromising on quality. It’s a substantial breakthrough and important step that will allow us to support mass-market adoption, transition to an industrial company, and speed up the development of other milk proteins.”

The facility allows Imagindairy access to production at more than 100,000 liters of fermentation capacity, with planned capacity expansion to triple this volume in the next one to two years. At present, Imagindairy is already producing industrial-scale batches in the facility at a competitive cost structure to traditional dairy. 

This achievement comes on the heels of another major company milestone, as Imagindairy received a “no questions” response letter from the U.S. Food & Drug Administration last month for the Generally Recognized as Safe (GRAS) notice submitted by the company. This signifies that the ingredient is safe to be used in food and beverage products, providing a regulatory ‘green light’ for food and beverage manufacturers to partner with Imagindairy. Imagindairy can now offer the most efficient manufacturing and end-to-end capabilities, extending through in-market product availability. 

Photo courtesy of Imagindairy.